Recent research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing encouraging results in addressing excess mass and type 2 disease. Initial information suggest a novel action contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/